基因灭活无细胞百日咳疫苗成人加强免疫随机对照非劣效试验
该随机对照非劣效试验纳入102名18-30岁澳大利亚成人,按2:1随机接种含基因灭活PT与FHA的aP2疫苗或已上市Tdap3疫苗。第28天aP2组PT-IgG和FHA-IgG血清转化率均非劣于Tdap3,PT-IgG与PTNA几何均值在28天和1年时均显著更高,安全性相当。
要点
- aP2疫苗第28天PT-IgG血清转化率98.5%,非劣于Tdap3的82.4%。
- aP2组PT-IgG与PTNA几何均值在28天和1年时均显著高于Tdap3组。
- 两组安全性相当,多数不良事件为轻至中度,严重不良事件与疫苗无关。
核心结论
- aP2疫苗在成人中安全,且免疫原性优于Tdap3疫苗,支持其作为百日咳加强疫苗使用。
研究设计与样本
- 随机对照非劣效试验,纳入102名18-30岁健康澳大利亚成人,按2:1随机接种aP2或Tdap3,并按婴儿期wP或aP初免分层。
主要发现
- 第28天PT-IgG血清转化率aP2为98.5%(95%CI 91.7-100.0),Tdap3为82.4%(65.5-93.2),绝对差16.1%。
- 第28天FHA-IgG血清转化率aP2为87.7%(77.2-94.5),Tdap3为61.8%(43.6-77.8),绝对差25.9%,均满足预设非劣效界值>-10%。
- 第28天PT-IgG几何均值aP2为132.70 IU/mL、Tdap3为57.42 IU/mL(p=0.0001);PTNA为146.97 IU/mL vs. 69.32 IU/mL(p=0.0010)。
- 接种后1年PT-IgG几何均值aP2为27.61 IU/mL、Tdap3为12.51 IU/mL(p=0.0099);PTNA为31.02 IU/mL vs. 15.70 IU/mL(p=0.0100)。
- 探索性分析显示wP初免和aP初免成人中aP2在两个时间点均诱导更高的PT-IgG和PTNA滴度。
关键数值与推荐
- 血清转化定义为抗体滴度较基线≥4倍升高。
- 预设血清转化非劣效界值为>-10%。
- 研究期间报告4例严重不良事件,均与疫苗无关。
临床怎么用
- 对于需要百日咳加强免疫的成人,aP2疫苗可能提供比Tdap3更强的PT-IgG和PTNA应答,且安全性相当。
局限性
- 样本量较小(102人),仅纳入18-30岁健康澳大利亚成人。
- 探索性分析结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Waning immunity after acellular pertussis (aP) vaccines shown in pertussis outbreaks highlights the need for more effective aP vaccines. We evaluated the immunogenicity and safety of a stand-alone 2-component aP vaccine (aP2) containing genetically inactivated pertussis toxin (PT) and filamentous hemagglutinin (FHA) compared with a licensed 3-component Tdap vaccine (Tdap3) containing chemically inactivated PT, FHA, and pertactin (PRN) in adults. METHODS: This randomized controlled trial enrolled 102 healthy Australian adults aged 18-30 years. Participants were randomized 2:1 (aP2: Tdap3) with stratification for priming in infancy with whole-cell (wP) or aP vaccines. Immunogenicity was assessed measuring serum PT-IgG, FHA-IgG and PT-neutralizing antibodies (PTNA) at baseline, Day-28 and 1-year post-vaccination. Seroconversion was defined as ≥4-fold rise in antibody titers from baseline. Safety was monitored throughout. RESULTS: Day 28 seroconversion rates for PT-IgG were 98.5% (95% CI 91.7-100.0) for aP2 and 82.4% (65.5-93.2) for Tdap3 (Δ, absolute difference = 16.1%) and for FHA-IgG 87.7% (77.2-94.5) for aP2 and 61.8% (43.6-77.8) for Tdap3 (Δ25.9%), meeting the pre-defined seroconversion non-inferiority margin of > - 10%. Geometric mean concentrations/titers of PT-IgG and PTNA were significantly higherin the aP2 group compared to Tdap3 at 28 days (PT-IgG 132.70 IU/mL vs. 57.42 IU/mL, p = 0.0001; PTNA 146.97 IU/mL vs. 69.32 IU/mL, p = 0.0010) and 1-year post-vaccination (PT-IgG 27.61 IU/mL vs. 12.51 IU/mL, p = 0.0099; PTNA 31.02 IU/mL vs. 15.70 IU/mL, p = 0.0100). Exploratory analysis showed aP2 elicited higher PT-IgG and PTNA titers in both wP- and aP-primed adults at both timepoints. Safety profiles were comparable between vaccines, with most adverse events being mild to moderate. Four serious adverse events were reported throughout the study, none of which were vaccine-related. CONCLUSION: These findings suggest that aP2 vaccine is safe and more immunogenic in adults compared with Tdap3 vaccine, supporting its use as a pertussis booster.
引用
- Ong MM, van den Biggelaar AHJ, Goh L, et al. Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial. Vaccine. 2026. PMID: 42349132. doi:10.1016/j.vaccine.2026.128863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。